Okidol (Ketoprofen Lysine)

Ketoprofen lysine works by inhibiting the cyclo‑oxygenase enzymes COX‑1 and COX‑2, which are required for prostaglandin synthesis. Lower prostaglandin levels decrease inflammation, pain signalling and fever, providing symptomatic relief at the site of injury or disease.

The appropriate dose of Okidol is determined by the prescribing clinician based on the patient’s condition, age, weight and renal‑hepatic function. The prescriber will set the strength, frequency and duration of therapy according to clinical guidelines.

Ketoprofen lysine, like other NSAIDs, is generally avoided in the third trimester of pregnancy because of potential fetal cardiovascular effects. It should only be used during pregnancy or lactation if the benefit outweighs the risk and after consultation with a healthcare professional.

To order Okidol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Okidol (ketoprofen lysine) offers a rapid onset of analgesia compared with some NSAIDs due to its lysine salt form, which improves gastrointestinal absorption. Its efficacy is comparable to ibuprofen or naproxen, while its safety profile aligns with class‑wide NSAID risks such as gastrointestinal and renal effects.

Okidol tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and heat. Keep the container tightly closed and out of direct sunlight.

Okidol is supplied as oral tablets that are swallowed whole with a full glass of water. It may be taken with or without food, although taking it with meals can reduce the likelihood of stomach upset.

Serious risks include gastrointestinal bleeding or ulceration, severe skin reactions such as Stevens‑Johnson syndrome, renal impairment, hepatotoxicity and increased cardiovascular events. Patients should be monitored for signs of bleeding, rash, changes in urine output or chest pain.

Okidol is contraindicated in individuals with known hypersensitivity to ketopro‑or any NSAID, active gastrointestinal ulcer disease, severe heart failure, advanced renal or liver failure, and in late‑term pregnancy. It should also be avoided in patients taking other NSAIDs unless specifically directed by a physician.